Merck will continue DTC for Singulair, Januvia, says CFO

Share this article:

In an analyst call, Merck EVP and CFO Peter Kellogg said the company plans “continued DTC efforts for Singulair and Januvia as well as appropriate promotional support for Gardasil, RotaTeq and Zostavax,” along with support for the launch of Isentress and hopeful Cordaptive.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.